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The consideration of a patient’s treatment preference may be essential in determining
how a patient will respond to a particular treatment. While traditional clinical trials are
unable to capture these effects, the two-stage randomized preference design provides an
important tool for researchers seeking to understand the role of patient preferences. In
addition to the treatment effect, these designs seek to estimate the role of preferences
through testing of selection and preference effects. The R package preference facilitates
the use of two-stage clinical trials by providing the necessary tools to design and analyze
these studies. To aid in the design, functions are provided to estimate the required sample
size and to estimate the study power when a sample size is fixed. In addition, analysis
functions are provided to determine the significance of each effect using either raw data or
summary statistics. The package is able to incorporate either an unstratified or stratified
preference design. The functionality of the package is demonstrated using data from
a study evaluating two management methods in women found to have an atypical Pap
smear.
Keywords: two-stage clinical trials, preference, sample size.
1. Introduction
In a traditional clinical trial setting, investigators are interested in determining the effect
of a treatment on a specified outcome. The conventional clinical trial design involves the
randomization of all patients to one of multiple treatment arms, which allows for the esti-
mation of this treatment effect. In addition to the treatment effect, the outcome may also
be influenced by a patient’s preference for one of the available treatment options, especially
in situations where the patient is not blinded to treatment assignment (e.g., surgical versus
medical intervention). Rucker (1989) proposed a two-stage trial design in order to address
this issue of patient preference. In the first stage, patients are randomized to either a choice
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or a random arm. In the second stage, patients in the choice arm are allowed to select their
preferred treatment, while patients in the random arm will undergo a second randomization
to one of the available treatment options. In addition to the treatment effect, the two-stage
design allows the estimation of two additional effects, the selection effect and the preference
effect. The selection effect refers to the additional effect of a patient’s preferred treatment on
the outcome, while the preference effect refers to the influence on the outcome of whether or
not a patient actually receives his/her preferred treatment.
In 2016, the two-stage randomized clinical trial design was extended to allow for the inclu-
sion of stratification factors (Cameron and Esserman 2018). The stratified version should
be employed if a patient’s treatment preference is expected to be closely related to a certain
measurable covariate. In this design, patients are stratified according to a specified stratifi-
cation variable prior to being assigned a treatment, either through choice or randomization.
For example, if older patients may be more likely to choose a medical intervention over a
surgical intervention, patients would be stratified by age before randomization.
This paper introduces the R (R Core Team 2020) package preference for the design and analy-
sis of two-stage (or doubly) randomized clinical trials for both the original Rucker (1989) ver-
sion (unstratified) and the stratified design by Cameron and Esserman (2018). This package
facilitates the implementation of the two-stage randomized design by providing the necessary
sample size estimation and analysis tools for clinicians and statisticians seeking to disentangle
the roles of patient preference in clinical trials. The package is available from the Comprehen-
sive R Archive Network (CRAN) at https://CRAN.R-project.org/package=preference
(Cameron 2020).
The preference package fits into the general category of the “Design and Analysis of Clinical
Trials” (Zhang and Zhang 2020) and focuses on Phase III trials. It is the first package to im-
plement both unstratified and stratified clinical trial designs incorporating patient preference.
The interface is simple and will readily fit into clinical trial framework packages.
2. The two-stage randomized trial
2.1. Trial design methodology
The general design, originally proposed by Rucker (1989), is illustrated in Figure 1. In this
design, patients are initially randomized to either the choice or the random group. Those
in the choice arm are then allowed to choose from the available treatment options, possibly
after a shared decision process with their physician or family; patients in the random group
are assigned a treatment through a second randomization. We assume that all patients have
a preferred treatment (i.e., no undecided patients). For simplicity, we present the case where
there are only two possible treatment choices.
Let N represent the total number of patients enrolled in the study and θ represent the
proportion of these patients initially randomized to the choice arm. Of note, work has been
done to estimate θ and determine the optimal allocation of participants into the choice and
random arms (Walter, Turner, Macaskill, McCaffery, and Irwig 2012). We use φ to represent
the proportion of patients who prefer treatment A; because we assume all patients have a
preference, we let 1 − φ represent the proportion of patients preferring treatment B.
The notations for the mean and standard deviation (SD) of each group are shown in Figure 1.






























Figure 1: The flow graph for the two-stage randomized preference trial.
We use µi and σi to represent the mean response and SD of patients randomized to treatment
i. µii and σii are used to represent the mean responses and standard deviations of patients
choosing treatment i. For the aspects of design discussed below, we assume σ1 = σ2 = σ11 =
σ22 = σ.
In cases where a treatment may not be equally preferred across the study population, the
above design can be extended to include important stratification variables (Cameron and
Esserman 2018). The notation is similar to that of the unstratified case, with the addition of
ξl used to denote the proportion of patients in stratum l (
∑s
l=1 ξl = 1).
2.2. Package overview
The design and analysis functions in preference assume a continuous, approximately normally
distributed outcome measure. Analyses may be conducted on raw data or summary data.
The raw data must contain the outcome variable of interest, treatment indicator, and arm
(i.e., choice or random). If the design is stratified, there must also be a stratum indicator.
The summary data must contain the mean and SD of the outcome, and sample size for each
arm by treatment combination. These should be broken down further by stratum if the
design is stratified. This package includes methods to compute treatment effects, standard
error estimates, test statistics, p values and (1 − α) confidence intervals for the preference,
selection, and treatment effects. In the functions preference() and fit_preference(),
the study results are computed from provided raw data. An alternative analysis function is
provided with fit_preference_summary(), which computes statistics using summary data.
Preference trial data structure
To aid in the design of the two-stage randomized trial, functions are provided to determine the
number of participants required to detect a treatment effect, preference effect, and/or selection
effect at a specified Type I and Type II error level (Turner, Walter, Macaskill, McCaffery,
and Irwig 2014; Cameron and Esserman 2018). A set of preference trials is parameterized as
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Parameter Column name Type
Preference sample size pref_ss numeric
Preference effect pref_effect numeric
Selection sample size selection_ss numeric
Selection effect selection_effect numeric
Treatment sample size treatment_ss numeric
Treatment effect treatment_effect numeric
Significance alpha numeric
Treatment ratio k numeric
in random arm
Patient proportion pref_prop list of vectors with
preferring treatment 1 1 numeric per stratum
Patient proportion in choice_prop numeric
choice arm
Patient proportion in stratum_prop list of vectors with
each stratum 1 numeric per stratum
Variance estimate of sigma2 list of vectors with
outcome of interest 1 numeric per stratum
Treatment power treatment_power numeric
Selection power selection_power numeric
Preference power pref_power numeric
Table 1: Columns and types of ‘preference.trial’ objects.
a ‘data.frame’ whose class attributes are ‘preference.trial’ and ‘data.frame’ with each
row corresponding to an individual trial. Each trial is parameterized by the parameters shown
in Table 1.
Functions are provided to construct ‘preference.trial’ objects based on three common sce-
narios. Each of these scenarios assume the effect sizes (pref_effect, selection_effect, and
treatment_effect), the proportions (pref_prop, choice_prop, stratum_prop), and distri-
butional parameters (k, alpha, sigma2) are known. When the sample size for each arm is
known the preference.trial() function may be used to specify a set of trials. For the more
common cases, when the maximum sample size of any arm is known, the pt_from_ss() func-
tion is used, and when the power must be above a threshold for each arm the pt_from_power()
function is used. Each of these functions may take vector arguments to create multiple trials
at once. When the lengths do not agree, value recycling occurs so that the number of rows
is equal to the argument vector with the longest length. As a result, sets of trials can be
quickly created based on many different configurations allowing the user to investigate the
trial characteristics and select the best trial from a large set of possible trials.
3. Case study: IMAP
In the Improving Management of Mildly Abnormal Pap Smears (IMAP) study, a two-stage
randomized trial design was used to evaluate psychosocial outcomes in women found to have
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atypical squamous cells of undetermined significance (ASCUS) with a Pap smear (McCaffery,
Irwig, Turner, Chan, Macaskill, Lewicka, Clarke, Weisberg, and Barratt 2010; McCaffery,
Turner, Macaskill, Walter, Chan, and Irwig 2011). In this study, the investigators sought to
determine whether women given an informed choice between two systems of management for
Pap smear abnormalities showed improvements in psychosocial outcomes, satisfaction, and
health-related quality of life (QOL) over women given no choice. The two arms were: (1)
standard management, i.e., repeated Pap testing every 6 months to monitor for more serious
abnormalities; and (2) use a human papilomavirus (HPV) triage approach, which tests for
the presence of HPV types that are associated with an increased risk of cervical cancer. The
original trial enrolled 330 women, 314 were randomized (16 did not meet eligibility criteria),
and 235 met criteria for inclusion in the analysis. A decision aid was used to support the
choice of women initially randomized to the choice arm of the study. The primary outcome for
this example is health related QOL measured with the mental component score (MCS) of the
36 question short form health survey (SF36; Ware Jr and Gandek 1994). While the original
trial did not stratify on any factors, for demonstration purposes, we stratified according to
the six item abbreviated state trait anxiety inventory (STAI; Marteau and Bekker 1992).
The STAI score is a measure of a person’s anxiety, with higher STAI scores indicating higher
levels of anxiety. A cutoff of 10 was the threshold for stratification (low versus high). We were
kindly provided with summary data for this trial by the original investigators. We used this
summary data to simulate a data set representative of the 208 individuals with stratification
information from the original trial. The simulated data raw set (imap), as well as summarized
versions of this data set (imap_summary and imap_stratified_summary) are available with
the package (see Section 3.3).
3.1. Sample size determination
Suppose we wish to estimate the required sample size to have sufficient power for detect-
ing treatment, preference, and selection effects for the SF36 MCS outcome in the IMAP
study. First, we need to define the size of the preference, selection, and treatment effects
we would like to detect. If the effect sizes are known, these effect sizes are used directly in
the pt_from_power function. If not, the function effects_from_means() can be used to
compute these effects from the means of each treatment group in both the choice and random
arm.
In the IMAP study, we may expect the HCV triage method to result in only a small increase
in SF36. That is, we expect women randomized to the HCV triage method to have a mean
SF36 score of 46 (µ1), while women randomized to repeated Pap screening to have a mean
SF36 score of 45 (µ2). In the choice arm, we expect the mean SF36 score to increase by 4
points in both management groups. Therefore, we assume that women choosing the HCV
triage method to have a mean score of 50 (µ11) and women choosing the repeated Pap smear
management option to have a mean SF36 of 49 (µ22). In addition, we must specify the
proportion of women preferring the HPV triage management method. Because management
with an HPV triage approach is generally a speedier option, we expect 70% (φ) of women to
prefer this approach, as compared to the 30% of women who would prefer management with
repeated Pap smears. With these assumptions, we can calculate the preference, selection and
treatment effects.
R> effects_from_means(mu1 = 46, mu2 = 45, mu11 = 50, mu22 = 49, phi = 0.7)







Therefore, with the mean SF36 scores assumed above, we need to design a study to detect a
treatment effect of 1, selection effect of 3.81, and a preference effect of 9.52. To determine the
necessary sample size, we must also specify the variance of the responses. In this example,
we assume a variance of 5 (σ2) for the SF36 outcome. Then, the sample sizes to detect the
above effects with 80% power and a Type I error of 0.05 is given by the pt_from_power()
function.
R> imap_trial <- pt_from_power(power = 0.8, pref_effect = 9.52,
+ selection_effect = 3.81, treatment_effect = 1, sigma2 = 5,




pref_ss pref_effect selection_ss selection_effect treatment_ss
1 23 9.52 224 3.81 314
treatment_effect alpha k pref_prop choice_prop stratum_prop sigma2
1 1 0.05 1 0.7 0.5 1 5
treatment_power selection_power pref_power
1 0.8 0.8 0.8
The function returns an object of class ‘preference.trial’ and ‘data.frame’. The trial
includes three samples sizes, pref_ss – the preference effect sample size, selection_ss – the
selection effect sample size, and treatment_ss – the treatment effect sample size. In order to
achieve at least 80% power for each of the effects, the largest sample size should be selected.
In this example, 314 patients are needed to detect the specified effects with at least 80% power
each with a Type I error rate of 5%. If all three of these effects are of primary interest, the Type
I error rate should be adjusted to account for multiple testing (e.g., Bonferroni correction).
Since it is common during the design phase to explore the effect on the sample size by varying
the power, a vector of power constraints can be specified returning a set of trial designs.
Additionally, a plot() function has been implemented to visualize the power vs. sample size
relationship, shown in Figure 2.
R> imap_trials <- pt_from_power(power = seq(0.7, 0.9, by = 0.01),
+ pref_effect = 9.52, selection_effect = 3.81, treatment_effect = 1,
+ sigma2 = 5, pref_prop = 0.7, alpha = 0.0167)
R> plot(imap_trials)
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Figure 2: The effect of varying the power on sample size in the IMAP trial design.
Sample size determination under stratification
We may also be interested in stratifying for STAI score (low vs. high) in our study. Because
women with low STAI scores have decreased anxiety, we expect women in this stratum to
have improved SF36 compared to women in the high STAI stratum. Therefore, we expect
women randomized to HCV triage with low STAI scores to have a mean SF36 of 52, while
women randomized to HCV triage with high STAI scores to have a mean SF36 of 42. In
addition, we assume that women randomized to repeated Pap screening will have a mean
SF36 of 50 in the low STAI stratum and a mean SF36 of 42 in the high STAI group.
In the choice arm, we expect both strata to have a small increase in SF36 across both manage-
ment systems. For the low STAI group, we expect a 2 point increase in mean SF36 for both
management groups. In the high STAI group, we also expect a 2 point increase in mean SF36
for women choosing repeated Pap screening. Because the HCV triage method is a speedier
approach, we expect a slightly greater increase in SF36 for women in the high STAI group
choosing this method; we assume a mean SF36 score of 46 for this group.
Finally, we assume that both management systems will be equally preferable to women in the
low STAI stratum (φ1 = 0.5). Because women with high STAI score have increased anxiety,
we may expect a greater proportion of these women to prefer the HPV triage management
method, which is the speedier option. Therefore, we assume that 70% of the women in the
high STAI stratum will prefer HPV triage, and only 30% will prefer repeated Pap screening
(φ2 = 0.7). Furthermore, we assume that 40% (ξ1) of women will have low STAI scores and
60% (ξ2) of women will be in the high STAI score stratum. Based on these assumptions, we
can calculate the preference, selection and treatment effects we wish to test in our study.
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R> effects_from_means(mu1 = c(52, 42), mu2 = c(50, 42), mu11 = c(54, 46),







With the assumptions listed above, we will need to design a study that can detect an overall
treatment effect of 0.8, selection effect of 3.14, and preference effect of 6.46. We also need to
specify the variance of the responses. We assume a variance of 3 for the SF36 outcome in
the low STAI stratum and a variance of 4 in the high STAI stratum. With 80% power and
a Type I error rate of 0.05, we can use the pt_from_power function to find the sample size
needed to detect the above effect.
R> pt_from_power(power = 0.8, pref_effect = 6.46, selection_effect = 3.14,
+ treatment_effect = 0.8, sigma2 = c(3, 4), pref_prop = c(0.5, 0.7),
+ stratum_prop = c(0.4, 0.6))
pref_ss pref_effect selection_ss selection_effect treatment_ss
1 25 6.46 157 3.14 354
treatment_effect alpha k pref_prop choice_prop stratum_prop sigma2
1 0.8 0.05 1 0.5, 0.7 0.5 0.4, 0.6 3, 4
treatment_power selection_power pref_power
1 0.8 0.8 0.8
In the two-stage randomized design stratified by STAI score, we would need an overall sample
size of 354 patients.
3.2. Power determination
Alternatively, we may have a pre-specified number of women to be enrolled (e.g., 208), or a
range of sample sizes to explore (e.g., 200 to 500 by 50) and instead want to know the power
of our study to detect each effect. If we assume the same preference, treatment, and selection
effects as above (Section 3.1) and make the same assumptions regarding the preference rate
and response variance, we can use pt_from_ss() to estimate the study power, assuming a
Type I error of 0.0167. The calculation below (row 6) shows with a sample size of 450, we
would have over 80% power for each of the effects, accounting for multiple testing with the
Bonferroni correction. As with the sample size determination, a visualization of the trials can
be created with the plot() function, whose output is shown in Figure 3.
R> pt_trials <- pt_from_ss(ss = seq(200, 500, by = 50), pref_effect = 9.52,
+ selection_effect = 3.81, treatment_effect = 1, sigma2 = 5,
+ pref_prop = 0.7, alpha = 0.0167)
R> pt_trials
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Figure 3: The effect of varying the power on sample size in the IMAP trial design.
pref_ss pref_effect selection_ss selection_effect treatment_ss
1 200 9.52 200 3.81 200
2 250 9.52 250 3.81 250
3 300 9.52 300 3.81 300
4 350 9.52 350 3.81 350
5 400 9.52 400 3.81 400
6 450 9.52 450 3.81 450
7 500 9.52 500 3.81 500
treatment_effect alpha k pref_prop choice_prop stratum_prop sigma2
1 1 0.0167 1 0.7 0.5 1 5
2 1 0.0167 1 0.7 0.5 1 5
3 1 0.0167 1 0.7 0.5 1 5
4 1 0.0167 1 0.7 0.5 1 5
5 1 0.0167 1 0.7 0.5 1 5
6 1 0.0167 1 0.7 0.5 1 5
7 1 0.0167 1 0.7 0.5 1 5
treatment_power selection_power pref_power
1 0.4375519 0.6020127 1
2 0.5425076 0.7161912 1
3 0.6350903 0.8035972 1
4 0.7138927 0.8675243 1
5 0.7790625 0.9126054 1
6 0.8316875 0.9434559 1
7 0.8733326 0.9640403 1
R> plot(pt_trials)
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Power determination under stratification
We may also wish to know our study power for a two-stage randomized trial stratified by
STAI score with 208 patients. We will continue to assume that we wish to detect a treatment
effect of 0.8, selection effect of 3.14, and preference effect of 6.46 and retain the assumptions
above regarding the variance and preference rate within each stratum.
R> pt_from_ss(ss = 208, pref_effect = 6.46, selection_effect = 3.14,
+ treatment_effect = 0.8, sigma2 = c(3, 4), pref_prop = c(0.5, 0.7),
+ stratum_prop = c(0.4, 0.6), alpha = 0.0167)
pref_ss pref_effect selection_ss selection_effect treatment_ss
1 208 6.46 208 3.14 208
treatment_effect alpha k pref_prop choice_prop stratum_prop sigma2
1 0.8 0.0167 1 0.5, 0.7 0.5 0.4, 0.6 3, 4
treatment_power selection_power pref_power
1 0.4038821 0.798997 1
Therefore, a stratified design with an overall sample size of 208 will have 40% power to detect
a treatment effect of 0.8, 100% power to detect a preference effect of 6.46, and 80% power to
detect a selection effect of 3.14 at an overall Type I error of 5% for the three tests.
3.3. Analyzing two-stage clinical trial data
Raw data for the primary outcome, SF36 MCS (outcome), is provided in the imap data frame
within the preference package.
R> head(imap)
outcome treatment arm strata
1 53.15752 HPV choice 1
2 56.15654 HPV choice 1
3 46.50584 HPV choice 1
4 48.39339 HPV choice 1
5 56.58280 HPV choice 1
6 49.21711 HPV choice 1
The treatment (HPV triage, "HPV", or repeated Pap screening, "Pap") is indicated in the
treatment column; the study arm is either the character value "choice" (denoting the choice
arm) or "random" (denoting the random arm) in the arm column; and the strata column
contains the stratum indicator: strata = 1 indicates the low STAI group and strata = 2
indicates the high STAI group.
Analyses can be conducted using one of the three functions: preference, fit_preference,
or fit_preference_summary. It is important to note, all three functions produce identical
output; they only vary in how the data is inputted.
Analyzing preference data with the formula interface
preference allows the user to enter the model description as a formula. The functionality is
similar to that of lm. The user is required to provided the formula and the data frame and
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has the option of specifying the Type I error rate (alpha), which is 0.05 by default. form
requires outcome, treatment, and arm (strata is only required if the design is stratified).
Unstratified call with default alpha:
R> pt_model <- preference(form = outcome ~ treatment:arm, data = imap)
Stratified call with alpha set at 0.1:
R> preference(form = outcome ~ treatment:arm | strata, data = imap,
























overall_pref_effect overall_pref_SE overall_pref_test overall_pref_pval
1 1.529016 3.050353 0.5012587 0.6161891
overall_pref_LB overall_pref_UB overall_sel_effect overall_sel_SE
1 -3.488368 6.5464 -5.179471 2.818095
overall_sel_test overall_sel_pval overall_sel_LB overall_sel_UB
1 -1.837934 0.06607217 -9.814824 -0.544118
overall_treat_effect overall_treat_SE overall_treat_test overall_treat_pval
1 1.087333 1.442818 0.7536179 0.4510787
overall_treat_LB overall_treat_UB
1 -1.285891 3.460558
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attr(,"class")
[1] "preference.fit"
The output is provided as a list: $alpha is the Type I error rate used for the confidence inter-
vals; $unstratified_statistics are the stratum specific statistics with each column corre-
sponding to a stratum; $overall_statistics are the statistics combined across the strata.
(note that for the unstratified case $unstratified_statistics and $overall_statistics
would be identical.) Both $unstratified_statistics and $overall_statistics contain
the effect estimate, standard error (SE), test statistic, p value, and (1 − α)100% upper and
lower bounds for each of the three effects (preference, pref; selection, sel; treatment, treat).
For this example, none of the overall effects are statistically significant at a Type I error rate
of 5%, although the overall selection effect is close to reaching statistical significance with a
p value of 0.07.
Analyzing data with the low-level interface
It is also possible to specify the data elements directly with fit_preference. The user is
required to provide the outcome, arm (the character that indicates if the arm is random,
"random", or choice, "choice"), and treatment. If the design is stratified, then strata,
an indicator of stratum is required. The default Type I error is 0.05, and can be changed
by varying alpha, which should be a value between 0 and 1. Analyzing unstratified data is
illustrated below using the imap data set.
R> out1 <- fit_preference(outcome = imap$outcome, arm = imap$arm,
+ treatment = imap$treatment)
The stratified version of this example is as follows.
R> out2 <- fit_preference(outcome = imap$outcome, arm = imap$arm,
+ treatment = imap$treatment, strata = imap$strata, alpha = 0.1)
Analyzing trial summary data
It may be that the raw data is unavailable and the user only has access to the summary
data. imap_summary and imap_stratified_summary contain the summary statistics for the
unstratified and stratified imap data set.
R> imap_summary
mean sd n treatment arm
1 47.451 9.172 49 HPV choice
2 47.696 9.736 74 HPV random
3 51.489 4.321 21 Pap choice
4 45.781 10.029 64 Pap random
R> imap_stratified_summary
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mean sd n treatment arm strata
1 53.175 4.517 24 HPV choice 1
2 41.957 9.192 25 HPV choice 2
3 53.005 5.080 10 Pap choice 1
4 50.111 3.120 11 Pap choice 2
5 51.163 6.399 30 HPV random 1
6 45.332 10.917 44 HPV random 2
7 54.017 5.419 22 Pap random 1
8 41.466 9.167 42 Pap random 2
The mean and sd columns indicate the mean and standard deviation of the SF36 MCS for each
study group. As with the raw data, treatment indicates the treatment, arm is a logical de-
noting the first stage randomization to choice or random, and in imap_stratified_summary,
strata indicates the stratum.
The fit_preference_summary function can be used to analyze the summary data by in-
putting the mean, variance, and sample size of each group.
R> out3 <- fit_preference_summary(x1mean = 47.451, x1var = 9.172^2, m1 = 49,
+ x2mean = 51.489, x2var = 4.321^2, m2 = 21, y1mean = 47.696,
+ y1var = 9.736^2, n1 = 74, y2mean = 45.781, y2var = 10.029^2, n2 = 64)
In a stratified design, the mean, variance, and sample size of each stratum must be included
along with the number of strata (nstrata) and the proportion of patients within each stratum
(xi). alpha may be varied from the default of 0.05 for both the stratified and unstratified
versions.
R> attach(imap_stratified_summary)
R> x1mean <- c(mean[1], mean[2])
R> x1var <- c(sd[1]^2, sd[2]^2)
R> m1 <- c(n[1], n[2])
R> x2mean <- c(mean[3], mean[4])
R> x2var <- c(sd[3]^2, sd[4]^2)
R> m2 <- c(n[3], n[4])
R> y1mean <- c(mean[5], mean[6])
R> y1var <- c(sd[5]^2, sd[6]^2)
R> n1 <- c(n[5], n[6])
R> y2mean <- c(mean[7], mean[8])
R> y2var <- c(sd[7]^2, sd[8]^2)
R> n2 <- c(n[7], n[8])
R> xi_1 <- sum(n[1], n[3], n[5], n[7])/sum(n)
R> xi <- c(xi_1, (1 - xi_1))
R> detach()
R> out4 <- fit_preference_summary(x1mean = x1mean, x1var = x1var, m1 = m1,
+ x2mean = x2mean, x2var = x2var, m2 = m2, y1mean = y1mean,
+ y1var = y1var, n1 = n1, y2mean = y2mean, y2var = y2var, n2 = n2,
+ xi = xi, nstrata = 2, alpha = 0.1)
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3.4. Optimal distribution between choice and random arms
In the examples presented above, we have assumed the choice proportion (choice_prop), the
proportion of individuals that are distributed to the choice arm, to be 0.5 (equal distribution).
In general, however, the choice proportion is not a fixed parameter and can be specified
according to the main goals of the study. If a desired choice proportion is known in advance,
the user can directly set this argument in the function calls above. If the desired choice
proportion is not known, the function optimal_proportion() can be used to estimate the
optimal value given the goals of a particular study (Walter et al. 2012).
To use optimal_proportion(), a set of weights must be defined that indicate the relative im-
portance of estimating each of the three effects (w_sel, w_pref, w_treat) with the constraint
w_sel + w_pref + w_treat = 1. For example, if we are equally interested in estimating the
selection, preference, and treatment effects, we would assign a weight of 13 to each effect (i.e.,
w_sel = w_pref = w_treat = 0.33). If we want to determine the optimal choice proportion
for the unstratified IMAP example above to detect a preference effect of 9.52 and a selection
effect of 3.81 (assuming 70% of women prefer the HCV triage method and a variance of 5),
we can use the following function call.
R> optimal_proportion(w_sel = 1/3, w_pref = 1/3, w_treat = 1/3, sigma2 = 5,
+ phi = 0.7, delta_pi = 9.52, delta_nu = 3.81)
[1] 0.6399756
Therefore, if we are equally interested in the estimation of the preference, selection, and treat-
ment effects, we should allocate 64% of patients to the choice arm in the initial randomization
stage.
Note, this function is only available for the unstratified design at this time, although work is
currently underway to expand this to the stratified case.
4. Summary
The two-stage randomized clinical trial design is an important tool for researchers seeking
to understand the impact of treatment preference on outcome. In cases where equivalence
has been demonstrated between two treatments, patient preferences may be an important
consideration for health care professionals seeking to provide the best possible treatment for
a particular patient. Estimation of the effect of treatment preference will also be of particular
interest when blinding is not feasible and when treatment success is closely tied to a patient’s
adherence.
This paper introduces the R package preference for the design and analysis of these trials. The
IMAP study discussed above is used to demonstrate the main functionality of the package.
To aid in the design of the two-stage randomized trial, sample size formulas are provided
to estimate the required sample size to detect a given preference, selection, and treatment
effect. In cases where the sample size is fixed, functions to compute the study power to detect
each effect are included. Finally, analysis functions are provided that can calculate the test
statistic, p value, effects estimates and 95% confidence intervals for each effect using either raw
or summary data. These functions can be used for both the unstratified and stratified study
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designs. In addition, the package provides tools for optimizing the distribution of patients in
the initial randomization between choice and random arm in the unstratified case.
This package is an important contribution as it is the first available software to design two-
stage clinical trials incorporating patient preference. Previous simulation studies are neither
available as part of supplementary material with the paper nor publicly available from the
investigators over the web. Extensions to the preference package are being actively developed
concurrently with extensions to the methodology. The above methods assume a continuous,
approximately normally distributed outcome measure; extensions to these methods are being
developed to allow for the design and analysis of studies with a binary or count endpoints.
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